ALS affects most major functions of the body, so Cedars-Sinai fights it from different directions, bringing together professionals from different fields of medicine. These specialists form an expert team to help patients find ways to face the disease.
The ALS Program also works closely with the Neurogenerative Diseases Laboratory and the Board of Governors Regenerative Medicine Institute to understand how neurodegenerative diseases work, which can then help in the development and testing of new treatments.
Charcot-Marie-Tooth/Hereditary Neuropathy Center
Charcot-Marie-Tooth (CMT), also called hereditary motor and sensory neuropathy (HMSN) and peroneal muscular atrophy, is an inherited neurological disorder that affects the peripheral nerves. There’s no cure for CMT yet, but patients at Cedars-Sinai have access to the country’s leading experts in CMT diagnosis and treatment, along with ongoing research studies and clinical trials.
There are many therapies and treatments available to help patients maintain muscle strength, reduce pain and cope with symptoms. Our neuromuscular specialists provide a care plan tailored to each patient.
The Charcot-Marie-Tooth/Hereditary Neuropathy Center is led by Neuromuscular Medicine Director Robert H. Baloh, MD, PHD, EMG Laboratory Director Richard Lewis, MD, FAAN, and Foot and Ankle Program Director Glenn B. Pfeffer, MD.